Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849038 · ClinicalTrials.gov registry record · Phase 2
Inflammation and Depression in People With HIV
A Phase 2 study of Depression and HIV, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05849038 is a Phase 2 study of Depression and HIV that is actively recruiting participants, run by Emory University. The registered enrollment target is 60 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05849038, a Phase 2 study of Depression and HIV, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing, functional MRI (fMRI) scans, and optional spinal taps as part of the study.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Baricitinib
Study Locations (2)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05849038
The ClinicalTrials.gov registry entry for NCT05849038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05849038 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05849038 about?
NCT05849038 is a clinical study titled "Inflammation and Depression in People With HIV". The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male ...
What is the current status of trial NCT05849038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-12-11. Estimated completion is 2027-11.
What conditions does trial NCT05849038 study?
This clinical trial studies the following conditions: Depression, HIV, Anhedonia.
What interventions are being tested in trial NCT05849038?
The interventions under investigation include: Placebo (OTHER), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT05849038?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849038 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.